Prestige BioPharma Limited

KSE 950210.KS

Prestige BioPharma Limited Price to Sales Ratio (P/S) on January 14, 2025: 1,238.05

Prestige BioPharma Limited Price to Sales Ratio (P/S) is 1,238.05 on January 14, 2025, a -62.74% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Prestige BioPharma Limited 52-week high Price to Sales Ratio (P/S) is 3,472.63 on June 12, 2024, which is 180.49% above the current Price to Sales Ratio (P/S).
Prestige BioPharma Limited 52-week low Price to Sales Ratio (P/S) is 746.99 on July 02, 2024, which is -39.66% below the current Price to Sales Ratio (P/S).
Prestige BioPharma Limited average Price to Sales Ratio (P/S) for the last 52 weeks is 2,039.02.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

KSE: 950210.KS

Prestige BioPharma Limited

CEO	Ms. So-Yeon Park
IPO Date	Feb. 9, 2021
Location	Singapore
Headquarters	21 Biopolis Road
Employees	66
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research, development, and marketing of biosimilars and new antibody therapeutics in the Asia Pacific. The company primarily engages in the development of new and similar antibody drugs for solid tumor, pancreatic cancer, breast cancer, gastric cancer, and arthritis. It is also developing vaccines for COVID-19 virus. The company was incorporated in 2015 and is headquartered in Singapore.

Key trends

Past 5 years